6505-01-509-4493 ( ZENAPAX 25 MG/MLIV )
NSN Information
| NSN | FSC | NIIN | Item Name | INC |
|---|---|---|---|---|
| 6505-01-509-4493 | 6505 | 015094493 | DACLIZUMAB | 7777 |
NSN Features
| MRC | Parameter | Characteristics |
|---|---|---|
| FEAT | SPECIAL FEATURES | OIMMUNOSUPPRESIVE HUMANIZED MONOCLONAL ANTIBODY PRODUCED BY RECOMINANT DNA TECHNOLOGY THAT BINDS SPECIFICALLY TO THE ALPHA SUBUNIT OF THE HUMAN HIGH-AFFINITY INTERLUKIN RECEPTOR THAT IS EXPRESSED ON THE SURFACE OF ACTIVATED LYMPHOCYTES; SUPPLIED AS CLEAR STERILE, COLORLESS CONCENTRATE FOR FURTHER DILUTION AND INTERVENOUS ADMINISTRATION IN SINGLE-USE GLASS VIALS; EACH VIAL CONTAINS 25 MG OF DACLIZUMAB IN 5ML OF SOLUTION; STORE BETWEEN 2-8 DEG C; DO NOT SHAKE OR FREEZE |
Manufacturing Part Numbers (SKUs)
| Part SKU | Cage | Status | RNVC | RNCC | SADC | DAC | RNAAC |
|---|---|---|---|---|---|---|---|
| ZENAPAX 25 MG/MLIV | 04493 | A | 2 | 3 | 4 | 9Z |
Manufacturers
| Part SKU | Cage | Manufacturer | Type | Status |
|---|---|---|---|---|
| ZENAPAX 25 MG/MLIV | 04493 | HOFFMANN-LA ROCHE INC. | F | A |
FLIS Identification
| PMIC | ADPE Code | CRITL Code | DEMIL Code | DEMIL INTG | NIIN Asgt | ESD | HMIC | ENAC | Schedule-B | INC |
|---|---|---|---|---|---|---|---|---|---|---|
| A | 0 | X | A | 1 | 06/23/2 | A | P | 7777 |
FLIS Management
| MOE | REC Rep Code | Mgmt Ctl | USC | Phrase Code | Phrase Statement |
|---|
Demilitarization Codes & Management
| DML | PMI | HMIC | ADP | CC | ESDC |
|---|
Miscellaneous Management
| MOE (S_A) | SOS | AAC | QUP | UI | SLC | CIIC | RC | MCC | SVC |
|---|
Management Control Army
| MATCAT 1 | MATCAT 2 | MATCAT 3 | MATCAT 4 5 | ARC |
|---|
Freight
| NMFC | NMFC SUB | UFC | HMC | LTL | LCL | WCC | TCC | SHC | ADC | ACC | ASH | NMF DESC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|